|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/19/23 Cell MedX Corp. 10-Q 11/30/22 53:2.4M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-Q Cell Medx Corp. - Form 10-Q SEC Filing HTML 555K
2: EX-10.67 Loan Agreement Dated April 11, 2023, Among Cell HTML 21K
Medx Corp. and Amir Vahabzadeh
3: EX-10.68 Loan Agreement Dated April 25, 2023, Among Cell HTML 21K
Medx Corp. and David Jeffs
4: EX-31.1 Certification of Principal Executive Officer HTML 19K
5: EX-31.2 Certification of Principal Financial Officer HTML 19K
6: EX-32.1 Certification of Principal Executive Officer HTML 16K
7: EX-32.2 Certification of Principal Financial Officer HTML 16K
13: R1 Document and Entity Information HTML 65K
14: R2 Condensed Consolidated Balance Sheets HTML 85K
15: R3 Condensed Consolidated Balance Sheets - HTML 23K
Parenthetical
16: R4 Condensed Consolidated Statements of Operations HTML 84K
17: R5 Condensed Consolidated Statement of Stockholders' HTML 80K
Deficit
18: R6 Condensed Consolidated Statements of Cash Flows HTML 70K
19: R7 Organization and Nature of Operations HTML 22K
20: R8 Related Party Transactions Disclosure HTML 36K
21: R9 Notes and Advances Payable Disclosure HTML 39K
22: R10 Other Current Assets Disclosure HTML 18K
23: R11 Equipment Disclosure HTML 23K
24: R12 Revenue Disclosure HTML 28K
25: R13 Notes and Advances Payable Disclosure, Current HTML 18K
26: R14 Share Capital Disclosure HTML 40K
27: R15 Subsequent Events Disclosure HTML 20K
28: R16 Related Party Transactions Disclosure: Schedule of HTML 24K
Amounts Due to Related Parties (Tables)
29: R17 Related Party Transactions Disclosure: Schedule of HTML 26K
Transactions with Related Parties (Tables)
30: R18 Notes and Advances Payable Disclosure: Schedule of HTML 29K
Loans and Advances Outstanding to Related Parties
(Tables)
31: R19 Equipment Disclosure: Change in book value of the HTML 22K
equipment (Tables)
32: R20 Revenue Disclosure: Schedule of Revenue and HTML 28K
Associated Costs (Tables)
33: R21 Share Capital Disclosure: Schedule of Stock Option HTML 25K
Activity (Tables)
34: R22 Share Capital Disclosure: Schedule of Warrant HTML 25K
Activity (Tables)
35: R23 Share Capital Disclosure: Schedule of Warrant HTML 21K
Details (Tables)
36: R24 Organization and Nature of Operations (Details) HTML 20K
37: R25 Related Party Transactions Disclosure: Schedule of HTML 29K
Amounts Due to Related Parties (Details)
38: R26 Related Party Transactions Disclosure: Schedule of HTML 30K
Transactions with Related Parties (Details)
39: R27 Notes and Advances Payable Disclosure: Schedule of HTML 29K
Loans and Advances Outstanding to Related Parties
(Details)
40: R28 Notes and Advances Payable Disclosure (Details) HTML 68K
41: R29 Other Current Assets Disclosure (Details) HTML 20K
42: R30 Equipment Disclosure: Change in book value of the HTML 24K
equipment (Details)
43: R31 Revenue Disclosure: Schedule of Revenue and HTML 40K
Associated Costs (Details)
44: R32 Notes and Advances Payable Disclosure, Current HTML 25K
(Details)
45: R33 Share Capital Disclosure: Schedule of Stock Option HTML 26K
Activity (Details)
46: R34 Share Capital Disclosure: Schedule of Warrant HTML 23K
Activity (Details)
47: R35 Share Capital Disclosure: Schedule of Warrant HTML 20K
Details (Details)
48: R36 Subsequent Events Disclosure (Details) HTML 30K
51: XML IDEA XML File -- Filing Summary XML 89K
49: XML XBRL Instance -- cmxc-20221130_htm XML 573K
50: EXCEL IDEA Workbook of Financial Reports XLSX 60K
8: EX-101.CAL XBRL Calculations -- cmxc-20221130_cal XML 51K
9: EX-101.DEF XBRL Definitions -- cmxc-20221130_def XML 213K
10: EX-101.LAB XBRL Labels -- cmxc-20221130_lab XML 383K
11: EX-101.PRE XBRL Presentations -- cmxc-20221130_pre XML 334K
12: EX-101.SCH XBRL Schema -- cmxc-20221130 XSD 95K
52: JSON XBRL Instance as JSON Data -- MetaLinks 188± 278K
53: ZIP XBRL Zipped Folder -- 0001393905-23-000233-xbrl Zip 110K
| Loan Agreement dated April 11, 2023, among Cell MedX Corp. and Amir Vahabzadeh |
LOAN AGREEMENT
THIS LOAN AGREEMENT (the “Agreement”) dated this 11th day of April, 2023
BETWEEN:
Amir Vahabzadeh of 1825 West King Edward Avenue, Vancouver, BC V6J 2W3, Canada
(the “Lender”)
OF THE FIRST PART
AND
Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA
(the “Borrower”)
OF THE SECOND PART
IN CONSIDERATION OF the Lender loaning certain monies (the “Loan”) to the Borrower, and the Borrower repaying the Loan to the Lender, both parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
Loan Amount & Interest
The Lender promises to lend ten thousand ($10,000.00) USD (the “Principal Amount”), to the Borrower and the Borrower promises to repay this Principal Amount to the Lender, at such address as may be provided in writing, with interest calculated and compounded monthly on the unpaid Principal Amount at the rate of 10.0% per annum.
Payment
This Loan is payable on demand. At any time while not in default under this Agreement, the Borrower may pay the outstanding balance then owing under this Agreement to the Lender without further bonus or penalty.
Default
Notwithstanding anything to the contrary in this Agreement, if the Borrower defaults in the performance of any obligation under this Agreement, then the Lender may declare the Principal Amount owing and interest due under this Agreement at that time to be immediately due and payable.
Governing Law
This Agreement will be construed in accordance with and governed by the laws of the Province of British Columbia.
Costs
All costs, expenses and expenditures including, without limitation, the complete legal costs incurred by enforcing this Agreement as a result of any default by the Borrower, will be added to the Principal Amount then outstanding and any accrued interest thereon, and will immediately be paid by the Borrower.
Binding Effect
This Agreement will pass to the benefit of and be binding upon the respective heirs, executors, administrators, successors and permitted assigns of the Lender. The Borrower waives presentment for payment, notice of non-payment, protest, and notice of protest.
Amendments
This Agreement may only be amended or modified by a written instrument executed by both the Borrower and the Lender.
Severability
The clauses and paragraphs contained in this Agreement are intended to be read and construed independently of each other. If any term, covenant, condition or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, it is the parties’ intent that such provision be reduced in scope by the court only to the extent deemed necessary by that court to render the provision reasonable and enforceable and the remainder of the provisions of this Agreement will in no way be affected, impaired or invalidated as a result.
General Provisions
Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this Agreement. Words in the singular mean and include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa.
Entire Agreement
This Agreement constitutes the entire agreement between the parties and there are no further items or provisions, either oral or otherwise.
IN WITNESS WHEREOF, the parties have duly affixed their signatures under hand and seal on this 11th day of April, 2023.
| Cell MedX Corp. | |
/s/ Amir Vahabzadeh |
|
|
|
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/15/24 Cell MedX Corp. 10-Q 2/29/24 53:2.7M Empire Stock Transf… Inc 1/16/24 Cell MedX Corp. 10-Q 11/30/23 46:2.3M Empire Stock Transf… Inc 10/16/23 Cell MedX Corp. 10-Q 8/31/23 42:1.9M Empire Stock Transf… Inc 9/01/23 Cell MedX Corp. 10-K 5/31/23 73:3.2M Empire Stock Transf… Inc 6/29/23 Cell MedX Corp. 10-Q 2/28/23 53:2.5M Empire Stock Transf… Inc |